S100A9 S100A8 Gene Expression Analysis for Septic Shock Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable test for determining a patient's susceptibility to nosocomial infections, particularly in patients with inflammatory systemic responses, and fail to effectively predict the progression of septic shock, leading to inappropriate treatments and potential serious side effects.
Innovation Solution
The analysis of S100A9 and S100A8 gene expression in biological samples, such as blood, using specific reagents like amplification primers, hybridization probes, or antibodies to determine susceptibility and prognosis of septic shock by comparing expression levels to established thresholds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard management with broad-spectrum antibiotics is used for all patients with septic syndrome, then treatment coverage is improved, but cost increases and patients are exposed to serious undesirable effects
Solution Approach 1:
The patent changes the parameter of treatment selection from universal broad-spectrum antibiotic administration to targeted therapy based on gene expression levels. By measuring S100A9 and S100A8 expression, the treatment approach is adjusted to match the actual risk level of each patient, avoiding unnecessary exposure to antibiotics and their side effects while maintaining adequate coverage for those who need it.
Solution Approach 2:
The patent enables the diagnostic system to self-determine which patients require intensive therapy through objective measurement of gene expression markers. The S100A9/S100A8 expression levels automatically identify high-risk patients without requiring clinical judgment, allowing the system to self-select patients for targeted treatment and avoid treating low-risk patients with intensive therapy.
2Reliability
If intensive therapy such as activated protein C is implemented for all patients with severe septic syndrome, then prognosis improvement is improved, but cost increases and patients are exposed to coagulation disorders
Solution Approach 1:
The patent introduces gene expression levels as a new parameter for determining prognosis and guiding intensive therapy decisions. By measuring S100A9 and S100A8 expression, the system identifies patients with poor prognosis who will benefit from intensive therapy, while sparing those with good prognosis from unnecessary treatment and its associated coagulation risks.
Solution Approach 2:
The patent establishes a feedback mechanism where gene expression measurement results directly influence treatment decisions. The S100A9/S100A8 expression levels provide real-time information about patient risk status, creating a closed-loop system where diagnostic data feeds back into therapeutic decision-making to optimize outcomes and minimize harm.
3Adaptability or versatility
If gene expression analysis of S100A9 and S100A8 is performed to determine susceptibility and prognosis, then treatment targeting is improved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts the specific diagnostic function of measuring S100A9 and S100A8 gene expression from the complex overall diagnostic process. By focusing on these two specific genes as surrogate markers, the patent simplifies the diagnostic approach while maintaining high adaptability for determining both susceptibility to nosocomial infection and prognosis of septic shock.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for accurate identification of patients at risk for nosocomial infections and predicts the progression of septic shock, enabling targeted treatments and improving patient outcomes by distinguishing between good and poor prognoses.
Implementation Method 1
hybridization probes
Implementation Method 2
antibodies
Data Source
AI summary
A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.